Chengwei Capital-backed Tot Biopharm secures $102m Series B funding

Tot Biopharm general manager Gloria Huang

Suzhou-headquartered biotechnology firm Tot Biopharm, which focuses on high-end anti-tumour drugs, has raised $102 million in a Series B funding round co-led by existing investor Chengwei Capital, asset manager 99Fund, and China Universal (Cayman) GP Ltd.

The latest funding round was also joined by investors that joined in earlier rounds, including Center Laboratories Group, Vivo Capital, Yuanta Financial Holdings Group, and Cathay Capital.

The fundraising came more than eight years after the company secured $6 million in its Series A funding round led by private equity firm Chengwei Capital in January 2010.

In a statement, Tot Biopharm said the fresh funds will be used to accelerate development of its key pipelines and to further finance its R&D, manufacturing, and marketing of high-end anti-tumour drugs.

Founded in 2010, Tot Biopharm now has over 10 drugs in the R&D stage, including three biologics and three small molecules, which have received investigational new drug application approvals, as well as one antibody-drug conjugate, which is expected to receive approval soon.

The firm is developing a biosimilar of bevacizumab, designated TAB008, for the treatment of solid tumours such as non-small cell lung cancer and colorectal cancer. It is also in the process of ramping up production of its third-generation innovative oncolytic virus drug TVP211.

“Tot Biopharm is taking advantage of the high-speed growth opportunities in China’s oncology market. In the future, we will also utilize the existing advantages of our established platforms to expand multi-perspective partnerships and cooperation at different levels, so that the benefits of resource integration will be maximized,” said Gloria Huang, the company’s general manager.

According to London-based L.E.K Consulting, China is the world’s second-largest pharmaceuticals markets after the US by sales, which were worth $123 billion last year. It is also a key growth market for drugs to treat cancer, with more than four million new cases diagnosed each year.

Between 2006 and 2011, the overall Chinese pharmaceutical market grew between 15 and 30 per cent per year, before tapering off slightly into the high teens in 2012-2013, according to a 2016 KPMG report.

In June, Chinese life sciences venture capital fund Pivotal bioVenture Partners China led the $16.5-million seed funding round in Oncologie, a Boston- and Shanghai-headquartered biopharmaceutical firm that targets cancer patients.

Also Read:

Australian cancer treatment firm Sirtex accepts $1.4b offer from China’s CDH

China’s Qiming Ventures leads $37m funding in AlphaBio Biopharma

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.